Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

PMID:
25173516
[PubMed - indexed for MEDLINE]
2.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators.

N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.

PMID:
23992602
[PubMed - indexed for MEDLINE]
Free Article
3.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, B├╝ller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

PMID:
23388003
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk